SOURCE: Xtalks

Xtalks Webinars

September 29, 2015 07:00 ET

Next Generation Sequencing as a Potential Tool to Assist Personalized Cancer Treatment, New Webinar Presented by Roche NimbleGen, Hosted by Xtalks

TORONTO, ON--(Marketwired - September 29, 2015) - On Tuesday, October 13, 2015 at 11am EDT / 4pm BST (UK GMT +1), esteemed speaker Dr. Karina Eterovic, will give a one-hour live presentation on this innovative topic. Dr. Eterovic is Associate Professor and Head of the Genomic Laboratory at the Institute for Personalized Therapy (IPCT) at MD Anderson Cancer Center.

Identifying and targeting specific genomic regions of interest are important to advancing our Next generation sequencing can significantly facilitate personalized cancer therapy approaches by identifying actionable somatic events in tumor samples. Furthermore, high-quality sequencing data can reveal associations with sensitivity or resistance that can inform the development and implementation of targeted therapeutics and, in particular, aid in the design of future trials to validate findings and actionability.

Whole genome (WGS) and whole exome sequencing (WES) allow the detection of SNVs, indels, CNVs, and some rearrangements. However, the relatively low coverage of WGS and WES, as currently implemented, may have limited ability to cost-effectively detect aberrations that are present in a subpopulation of tumor cells while identifying a myriad of aberrations of unknown clinical significance, thus lacking both sensitivity and specificity and complicating the analysis of the resulting data.

Deep targeted sequencing that allows detection of relatively low mutant allele frequency (MAF) may represent an alternative or a complement to WGS and WES to detect clinically relevant alterations. Additionally, in most clinical and research settings, the amount of DNA that can be isolated from tumor samples is limited and the DNA is often damaged due to fixation and storage procedures, such as formalin fixed paraffin embedded (FFPE) samples. Therefore a multiplexed targeted platform that can generate reliable data with high sensitivity from limited amounts of DNA from FFPE is needed. The details of the design and implementation of a targeted sequencing platform are important as they influence the precision and reliability of the molecular profiling results, impacting both translational research and clinical decision-making.

To learn more about this event visit: Next Generation Sequencing as a Potential Tool to Assist Personalized Cancer Treatment

Roche NimbleGen is an innovator in the life sciences market focused on research activities and manufacturing target enrichment probe pools for DNA sequencing. Capitalizing on the efficiencies inherent with parallel enrichment, researchers can now design economical, high throughput, and time-saving next-generation sequencing experiments. Next-generation sequencing combined with Sequence Capture probe pools offers researchers a clearer understanding of genomic structure and function in order to understand the impact of genes on biological processes. We are part of the innovations in sequencing solutions for life science research, now and in the future.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2015/9/28/11G060765/Images/ROCHE_logo-sm-438380682449.jpg

Contact Information